KQ-2003

N/A

Report date: 2025/02/21 16:20:17

Base Information

Drug NameKQ-2003
Drug Alias NameKQ-2003KQ2003
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-cell maturation protein modulators +[4] 
TargetsB-cell maturation proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsSolid tumoursPOEMS SyndromeMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Keqi Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Keqi Pharmaceutical Technology Co LtdErigen LlcNovatim Immune Therapeutics (Zhejiang) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursPOEMS SyndromeMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A